RICS:NVP.ST

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

LUND, Sweden, Oct. 18, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive andRamin Massoumi at Lund University have been granted 2.5 MSEK from the Swedish Foundation for Strategic Research (SFF...

2017-10-18 15:05 1889

NeuroVive's Collaborator, the Children's Hospital of Philadelphia Awarded NIH Grant to Study NVP015 Against Chemical Threats

LUND, Sweden, Oct. 6, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (NASDAQ Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its research collaboration partner the Children's Hospital ofPhiladelphia (CHOP) has received a two-year grant, #1R21NS103826-01f ...

2017-10-06 05:44 1528

NeuroVive Appoints Daniel Schale as Director of Communications

LUND, Sweden, Oct. 4, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced the appointment ofDaniel Schale as Director of Communications. Daniel will report to CFOCatharina Johansson. Daniel Schale will be res...

2017-10-04 15:00 1264

NeuroVive and Yungjin Pharm Start Clinical Development in Genetic Mitochondrial Disease

LUND, Sweden and SEOUL, South Korea, June 27, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the clinical phase I study of KL1333 has started in Korea and that...

2017-06-27 17:17 3280

NeuroVive Receives Research Grant From Vinnova for Development of the NVP015 Genetic Mitochondrial Disease Project

LUND, Sweden, June 1, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseas...

2017-06-01 19:52 3200

NeuroVive to Continue NeuroSTAT® Clinical Development After Positive Outcome in Preclinical and Clinical TBI Studies

LUND, Sweden,, May 23, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced positive results from clinical and preclinical studies with its drug NeuroSTAT® for the prevention of the sequelae of traumatic brain injury (TBI). The company is now prep...

2017-05-23 15:04 3898

NeuroVive Pharmaceutical AB Interim Report January - March 2017

STOCKHOLM, May 18, 2017 /PRNewswire/ -- Broadened project portfolio Business operations Significant events January-March 2017 * Strong inhibitory effects demonstrated in human hepatocellular carcinoma cells and in an experimental model of liver cancer with the Company's new generation of s...

2017-05-18 15:18 2635

NeuroVive Invitation to Conference Call and Web Cast on in-licensing Agreement With Yungjin Pharm

LUND, Sweden, May 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") invites to a conference call and webcast tomorrow,3 May 2017, at 2:00 pm CEST, to present the in-licensing agreement with Yungjin Pharm that was announced this morning. Erik ...

2017-05-02 15:01 2325

NeuroVive in-licenses a Genetic Mitochondrial Disease Clinical Stage Project From Yungjin Pharm

LUND, Sweden and SEOUL, South Korea, May 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced that they have entered into a global licensing agreement on Yungjin P...

2017-05-02 11:51 2667

NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects

LUND, Sweden, April 20, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive")today announced positive preclinical results demonstrating anti-fibrotic effects with NV556, the company's preclinical compound for non-alcoholic steatohepatitis (NASH), in ...

2017-04-20 15:05 2476

NeuroVive's Lead NASH Project to be Presented at The International Liver Congress(TM)

LUND, Sweden, April 5, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),the mitochondrial medicine company, today announced that an abstract with preclinical data related to the company's lead project for non-alcoholic steatohepatitis (NASH) has been accepted...

2017-04-05 17:32 2539

Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)

LUND, Sweden, March 31, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 23,328. This is a result of a performed subscription options program (...

2017-03-31 19:23 2626

NeuroVive Pharmaceutical AB Publishes 2016 Annual Report

LUND, Sweden, March 23, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for 2016 is now available on the company's website www.neurovive.com

2017-03-23 16:45 2511

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB

LUND, Sweden, March 23, 2017 /PRNewswire/ -- The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place onThursday, April 27, 2017, at 4 pm at Medicon Village, Scheelevagen 2 in Lund, Sweden. Please see the attached not...

2017-03-23 16:13 2553

NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma

LUND, Sweden, Feb. 22, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),the mitochondrial medicine company, today announced two new research agreements and the appointment of ProfessorPhilippe Gallay, PhD, and Professor Massimo Pinzani, MD, PhD, FRCP, as scie...

2017-02-22 19:05 2067

NeuroVive Pharmaceutical AB Year End Report January - December 2016

STOCKHOLM, Feb 21, 2017 /PRNewswire/ -- Important steps forward and new research collaborations Business operations Important events October – December 2016 * The development of CicloMulsion for acute kidney injury was discontinued and as a consequence, the value of the subsidiary NeuroVive A...

2017-02-21 16:01 2207

NeuroVive's new Generation of Sanglifehrin-based Compounds Demonstrate Potent Inhibitory Effects on Human Hepatocellular Cancer Cells

LUND, Sweden, Feb. 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, presents preclinical data from a new generation of sanglifehrin-based compounds with potent inhibitory effects on hepatocellular carcinoma (HCC) cells...

2017-02-02 16:47 3974

NeuroVive Redirects Research Resources From Asian Subsidiary to Parent

Lund, Sweden, Jan 25, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that itsTaiwan-based subsidiary's research resources and activities will be redirected to the parent company NeuroVive Pharmaceutical ...

2017-01-25 16:09 2750

NeuroVive Signs Mitochondrial Medicine Research Agreement With US key Opinion Leader

LUND, Sweden, Jan. 23, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),today announces that NeuroVive has signed a preclinical collaboration agreement with the Children's Hospital ofPhiladelphia (CHOP) andMarni J. Falk, M.D., a US key opinion leader in the m...

2017-01-23 16:03 2753

NeuroVive Presents Positive Preclinical Data in Hepatocellular Cancer at HCC Summit

LUND, Sweden, Jan. 19, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer data related to the company's sanglifehrin-based compounds has been accepted for present...

2017-01-19 17:58 2547
1234

Week's Top Stories